News

AddToAny

Google+ Facebook Twitter Twitter

CJD treatment trialled for first time

In a world first, doctors have been given permission to give a British man with CJD a pioneering treatment.

CJD is a rare but lethal brain disease for which there is no known cure, but the Court of Protection has given permission for the trial use on a human for the first time.

Scientists say lab testing of the man-made antibody has been encouraging, but they admit they do not know how their patient will respond.

The treatment is called PRN100 and aims to prevent abnormal prions from being able to attach themselves to healthy proteins, meaning that they cannot grow and cause devastation throughout the brain.

University College London Hospitals NHS Foundation Trust (UCLH) is set to use it in a patient for the first time after a judge confirmed that it was lawful.

Professor John Collinge, Director of the Medical Research Council Prion Unit at UCLH, who led the development of the treatment, said: “As this is the first time this treatment has been used in humans we cannot predict what the outcome will be, but laboratory testing has shown the potential to treat prion infection.”


Image credit | iStock

Related Articles

Predicting obesity-related disease

Scientists have found a new way to use molecular “signatures” from people with obesity to predict risk of developing diabetes and cardiovascular disease.

Mouse pups with same-sex parents born

Researchers at the Chinese Academy of Sciences were able to produce healthy mice with two mothers that went on to have normal offspring of their own.

Leeds-Digital-pathology-©mearnsandpike760A4908.jpg

Total digital pathology

A histopathology lab in Leeds is the first of its kind to go 100% digital. Here we mark the milestone, while Chloe Lockwood explains the workflow and Basharat Hussain unpicks some of the challenges that were overcome.

Early results for gene editing study

Early, partial results from a historic gene editing study indicate that the treatment may be safe and having at least some of its hoped-for effect.

Top